Research progress of HHLA2/TMIGD2 in solid tumors
10.3872/j.issn.1007-385x.2019.12.018
- VernacularTitle:HHLA2/TMIGD2在实体肿瘤中的研究进展
- Author:
SUN QI
1
;
LI Jingjing
2
;
LIU Bin
3
Author Information
1. Department of Pathology of the 940th Hospital of the Joint Logistics support Force of the Chinese people's Liberation Army, Institute of Pathology, School of basic Medicine, Lanzhou University
2. Basic Medical College of Gansu University of traditional Chinese Medicine
3. Department of Pathology of the 940th Hospital of the Joint Logistics support Force of the Chinese people's Liberation Army
- Publication Type:Review
- Keywords:
人内源性逆转录病毒-H长末端重复关联蛋白2 (HHLA2)；穿膜和免疫球蛋白结构域2(TMIGD2)；实体肿瘤；程序性死亡 因子 1（PD-1）；程序性死亡因子配体1（PD-L1）；免疫治疗
- From:
Chinese Journal of Cancer Biotherapy
2019;26(12):1405-1409
- CountryChina
- Language:Chinese
-
Abstract:
以程序性死亡因子 1（PD-1）及其配体 1（PD-L1）为代表的B7/CD28家族在肿瘤免疫治疗中显示出极大的应用潜力，但仍 有很多PD-L1检测阴性患者无法从中受益。作为B7家族成员，人内源性逆转录病毒-H长末端重复关联蛋白2 (HHLA2)分子结 构与PD-L1等其他B7家族成员有一定的同源性和相似性， 对T细胞有共刺激和共抑制作用，在多数实体肿瘤中呈高表达，且在某 些实体肿瘤中表达比PD-L1更广泛；其通过与受体穿膜和免疫球蛋白结构域2(TMIGD2)结合可促进肿瘤免疫逃逸，导致肿瘤的 进展和转移。基于此，HHLA2/TMIGD2有望成为肿瘤免疫治疗新的通路和靶点之一。本文就HHLA2及其受体TMIGD2的分子 结构、生物学功能及其在实体肿瘤中作用的研究进展作一综述。
- Full text:20191218.pdf
